Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1078656 | 1.00 | CA2 (0.44) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL4402227 | 1.00 | CA2 (0.44) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL31370603 | 0.88 | CA2 (0.42) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL7154999 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL18817541 | 0.86 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL11190794 | 0.86 | CA2 (0.41) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL22841212 | 0.84 | CA2 (0.40) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL10810001 | 0.84 | CA2 (0.40) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL31362250 | 0.84 | CA2 (0.40) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL935836 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016112088-A1 | ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| WO-2016112088-A1 | ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS | SPERO THERAPEUTICS, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| CN-103974948-A | Substituted benzyl indazoles as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | Bayer Pharma AG | 2014-08-06 | — | — | CN | disclosed |
| US-8513443-B2 | Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-3,4-difluoro-2(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide | ARDEA BIOSCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513443-B2 | Preparation of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and (S)-N-3,4-difluoro-2(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide | ARDEA BIOSCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120178946-A1 | PREPARATION OF (R)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND (S)- N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE | ARDEA BIOSCIENCES ,INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178946-A1 | PREPARATION OF (R)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND (S)- N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE | ARDEA BIOSCIENCES ,INC. (US) | 2012-07-12 | — | — | US | disclosed |
| CN-102471246-A | Preparation of and (S) -N- (3, 4-difluoro-2- (2-fluoro-4-iodophenylamino) -6-methoxyphenyl) -1- (2, 3-dihydroxypropyl) cyclopropane-1-sulfonamide and protected derivatives thereof | ARDEA BIOSCIENCES INC | 2012-05-23 | — | — | CN | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178946-A1 | PREPARATION OF (R)-N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE AND (S)- N-(3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMIN0)-6-METHOXYPHENYL)-1-(2,3-DIHYDROXYPROPYL)CYCLOPROPANE-1-SULFONAMIDE | DHPS, SPNS2, SULT2A1 | CA2 1690/4885ALDH1A1 462/4885NPSR1 44/4885 |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS1, NOS3, NOS2 | CA2 690/4885ALDH1A1 954/4885NPSR1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.